RxDoctor Payments Data

Munaf Alkadimi, MD

Internal Medicine · Houston, TXNPI 1457882870

Payments from drug & device makers

$15,605in general payments, 2019–2025

Across 242 payments — averaging $64.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • Regeneron$4K
  • Incyte Corporation$1K
  • Astellas Pharma US Inc$471
  • E.r. Squibb & Sons, L.L.C.$452
  • Johnson & Johnson$432
  • plus $5K from 45 others

What the payments were for

  • Consulting fees$8,22953%
  • Food & beverage$6,62542%
  • Education$7515%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,605 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$1,086,807
Medicare patients
240
Services billed
85,726

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide52$861,076
Lenalidomide31$499,086
JakafiRuxolitinib Phosphate33$493,049
VerzenioAbemaciclib35$489,880
ImbruvicaIbrutinib23$207,663
LynparzaOlaparib12$199,710
Abiraterone Acetate56$134,183
EliquisApixaban95$74,281
ThalomidThalidomide13$63,449
Imatinib Mesylate25$58,231
XareltoRivaroxaban48$58,104
AranespDarbepoetin Alfa In Polysorbat30$24,834
Granisetron Hcl34$12,329
Aprepitant29$10,099
OxycontinOxycodone Hcl12$9,982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid, Thalomid$305$924,52565 claims
Incyte CorporationJakafi$1,299$493,04933 claims
Lilly USA, LLCVerzenio, Olanzapine$198$490,13874 claims
AstraZenecaLynparza$4,411$199,71012 claims
PfizerEliquis$243$74,28195 claims
Johnson & JohnsonXarelto$432$58,10448 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →